Floatz logo

8 assets in Pulmonary Large Cell Neuroendocrine Carcinoma

Therapeutic assets addressing Pulmonary Large Cell Neuroendocrine Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
[203Pb]Pb-MP0712
Pulmonary Large Cell Neuroendocrine Carcinoma
Molecular Partners AGP1/2CCC (48)
[212pb]pb-mp0712
Pulmonary Large Cell Neuroendocrine Carcinoma
Molecular Partners AGP1/2CCC (48)
Tarlatamab
Pulmonary Large Cell Neuroendocrine Carcinoma
University of ArizonaP1/2CC (47)
111in-etn029
Pulmonary Large Cell Neuroendocrine Carcinoma
Novartis PharmaceuticalsP1CC (43)
225ac-abd147
Pulmonary Large Cell Neuroendocrine Carcinoma
Abdera Therapeutics Inc.P1CC (43)
225ac-etn029
Pulmonary Large Cell Neuroendocrine Carcinoma
Novartis PharmaceuticalsP1CC (43)
lb2102
Pulmonary Large Cell Neuroendocrine Carcinoma
Legend Biotech USA IncP1CC (43)
Bl-M14D1
Pulmonary Large Cell Neuroendocrine Carcinoma
SystImmune Inc.P1NR ()